Journey Medical (DERM) Research & Development (2021 - 2026)

Journey Medical (DERM) has reported Research & Development for 6 consecutive years, with $54000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development changed N/A year-over-year to $54000.0; the trailing twelve-month figure through Jun 2026 stood at $495000.0 (down 54.96% YoY), and the FY2025 full-year result was $480000.0, down 95.13% from the prior year.
• Research & Development slipped to $54000.0 in Q2 2026 per DERM's latest filing, from $154000.0 in the prior quarter.
• Across five years, Research & Development topped out at $7.9 million in Q1 2024 and bottomed at $39000.0 in Q1 2025.
• Historically, Research & Development has averaged $1.8 million across 5 years, with a median of $1.4 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 8896.55% in 2022, then plunged 99.51% in 2025.
• Over 5 years, Research & Development stood at $4.3 million in 2022, then tumbled by 64.64% to $1.5 million in 2023, then sank by 85.51% to $218000.0 in 2024, then slipped by 29.36% to $154000.0 in 2025, then plunged by 64.94% to $54000.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $54000.0, $154000.0, and $287000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.